Dipti Amin - Net Worth and Insider Trading

Dipti Amin Net Worth

The estimated net worth of Dipti Amin is at least $48,300 dollars as of 2023-03-21. Dipti Amin is the Director of Lineage Cell Therapeutics Inc and owns about 35,000 shares of Lineage Cell Therapeutics Inc (LCTX) stock worth over $48,300. Details can be seen in Dipti Amin's Latest Holdings Summary section.

Transaction Summary of Dipti Amin


Dipti Amin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dipti Amin owns 1 companies in total, including Lineage Cell Therapeutics Inc (LCTX) .

Click here to see the complete history of Dipti Amin’s form 4 insider trades.

Insider Ownership Summary of Dipti Amin

Ticker Comapny Transaction Date Type of Owner
LCTX Lineage Cell Therapeutics Inc 2021-04-20 director

Dipti Amin Latest Holdings Summary

Dipti Amin currently owns a total of 1 stock. Dipti Amin owns 35,000 shares of Lineage Cell Therapeutics Inc (LCTX) as of March 28, 2022, with a value of $48,300.

Latest Holdings of Dipti Amin

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
LCTX Lineage Cell Therapeutics Inc 2022-03-28 35,000 1.38 48,300

Holding Weightings of Dipti Amin

Dipti Amin Form 4 Trading Tracker

According to the SEC Form 4 filings, Dipti Amin has made a total of 1 transactions in Lineage Cell Therapeutics Inc (LCTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lineage Cell Therapeutics Inc is the acquisition of 35,000 shares on March 28, 2022, which cost Dipti Amin around $57,050.

Insider Trading History of Dipti Amin

Insider Trading Shares
Shares Change
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
Lineage Cell Therapeutics Inc
Total 1
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dipti Amin Trading Performance

GuruFocus tracks the stock performance after each of Dipti Amin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Dipti Amin is -3.38%. GuruFocus also compares Dipti Amin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Dipti Amin within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Dipti Amin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Dipti Amin

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) -16.89 -3.38 -20.95
Relative Return to S&P 500(%) -10.6 13.1 -2.23

Dipti Amin Ownership Network

Ownership Network List of Dipti Amin

No Data

Ownership Network Relation of Dipti Amin

Dipti Amin Owned Company Details

What does Lineage Cell Therapeutics Inc do?

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Who are the key executives at Lineage Cell Therapeutics Inc?

Dipti Amin is the director of Lineage Cell Therapeutics Inc. Other key executives at Lineage Cell Therapeutics Inc include Chief Financial Officer Jill Ann Howe , General Counsel/Secretary Samuel George A. Iii , and Chief Financial Officer Kevin Leon Cook .

Lineage Cell Therapeutics Inc (LCTX) Insider Trades Summary

Over the past 18 months, Dipti Amin made 1 insider transaction in Lineage Cell Therapeutics Inc (LCTX) with a net purchase of 35,000. Other recent insider transactions involving Lineage Cell Therapeutics Inc (LCTX) include a net purchase of 930,106 shares made by Broadwood Partners Lp , a net sale of 539,283 shares made by Gary S. Hogge , and a net purchase of 7,000 shares made by Michael H. Mulroy .

In summary, during the past 3 months, insiders sold 0 shares of Lineage Cell Therapeutics Inc (LCTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 539,283 shares of Lineage Cell Therapeutics Inc (LCTX) were sold and 977,356 shares were bought by its insiders, resulting in a net purchase of 438,073 shares.

Lineage Cell Therapeutics Inc (LCTX)'s detailed insider trading history can be found in Insider Trading Tracker table.


AMEX:LCTX Insider Transactions

Total 0
Shares Owned
Trade Price($)
Trade Percentage(%)
Price change since trade(%)
Share ownership details
Filing Date
Total 0

Dipti Amin Mailing Address

Above is the net worth, insider trading, and ownership report for Dipti Amin. You might contact Dipti Amin via mailing address: C/o Lineage Cell Therapeutics, Inc., 2173 Salk Avenue, Suite 200, Carlsbad Ca 92008.